GE Healthcare’s DaTSCAN recommended in EFNS guidelines

GE Healthcare has won a recommendation for its radiopharmaceutical agent DaTSCAN in new Alzheimer's disease management guidelines from the European Federation of the Neurological Societies (EFNS).

The ioflupane I 123 injection, which is used in conjunction with single photon emission-computed tomography (SPECT) imaging of the brain, has been endorsed as a means of making it easier to differentiate Alzheimer's from dementia with Lewy bodies.

These two conditions can often be confused when analysing dopaminergic SPECT imaging of the brain, with the EFNS noting that DaTSCAN can deliver sensitivity of around 85 per cent for this function.

Adrian Holden, European head of medical professional services for GE Healthcare, said the rising prevalence of dementia will make this an important quality for healthcare professionals in future.

"Neurologists will become increasingly reliant on imaging technologies that can accurately yield a definitive diagnosis," he explained.

Earlier this month, the company launched Infinia Hawkeye HD Enhanced, an advanced new version of its groundbreaking Infinia Hawkeye SPECT/CT system.